Active Ingredient History
Urokinase, also known as urokinase-type plasminogen activator (uPA), is a serine protease present in humans and other animals. The human urokinase protein was discovered, but not named, by McFarlane and Pilling in 1947. Urokinase was originally isolated from human urine, and it is also present in the blood and in the extracellular matrix of many tissues. The primary physiological substrate of this enzyme is plasminogen, which is an inactive form (zymogen) of the serine protease plasmin. Activation of plasmin triggers a proteolytic cascade that, depending on the physiological environment, participates in thrombolysis or extracellular matrix degradation. This cascade had been involved in vascular diseases and cancer progression. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Arterial Occlusive Diseases (Phase 3)
Chronic Limb-Threatening Ischemia (Phase 3)
Coronary Artery Disease (Phase 4)
Diabetic Foot (Phase 3)
Empyema (Phase 3)
Empyema, Pleural (Phase 4)
Hemothorax (Phase 3)
Infections (Phase 3)
Ischemia (Phase 3)
Ischemic Stroke (Phase 3)
Peripheral Arterial Disease (Phase 2)
Pleural Diseases (Phase 4)
Pleural Effusion (Phase 4)
Pneumonia (Phase 3)
Pulmonary Embolism (Phase 4)
Stroke (Phase 3)
Thromboembolism (Phase 4)
Thrombosis (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
